NXTC

NASDAQ 已收盘

NextCure

6.45 USD
▼-0.33-4.87%
盘后 6.17 -4.34%
2026-11-20
市值
$29.53M
市盈率
—
EPS
-8.26
股息率
—
52 周区间
1.55 – 15.74
成交量
30.88K
Beta
1.20
目标价
20.00
52W 低 1.5552W 高 15.74
价格走势

公司简介

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in advancing medicines to treat cancer. The company’s product candidate is the LNCB74, a B7-H4 targeted ADC to kill tumors. It also develops NC410, a fusion protein of LAIR-2, that is designed to block immune suppression mediated by LAIR-1; NC525, a novel LAIR-1 antibody that targets acute myeloid leukemia, blast cells, and leukemic stem cells; NC181 a humanized antibody targeting ApoE4 for the treatment of Alzheimer’s disease; and NC605 an antibody that targets Siglec-15, as w...